New Drug Design, Biological Assessment Expert Consultant ResumeThis expert specializes in the pharmaceutical industry, new drug design, and synthesis. Further expertise includes biological assessment, early drug development, and clinical trials.
This expert has conducted numerous studies in areas including biochemistry and pharmacology, radiopharmaceuticals, inflammatory bowel disease, and molecular. Further studies has included pharmacological and clinical aspects of nitric oxide, inflammation / arthritis, and osteoarthritis therapy.
This consultant's experience includes marketing, clinical research, safety, and chemical scale-up of identification and advancement of novel potential drugs. Further experience includes scientific guidance to the medicinal chemistry, excellent communications between chemistry sites and between chemists and biologists, bringing a compound to clinical trials, and coordination of medicinal chemical research.
Consultant, Kevin Kennedy Associates Inc.
Providing expertise in chemistry, pharmaceuticals, new drug design, biological assessment, research science, inventing, and related expertise to a wide variety of clients.
Adjunct Associate Professor of Medicinal Chemistry, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, major university
President, pharmaceutical consulting firm
Discovery/Early Development Consulting to the Pharmaceutical industry, with emphasis on medicinal chemistry.
Senior Research Advisor and Science Fellow, Discovery Medicinal Chemistry, Pharmacia Corp; Pfizer Inc.
Chemistry Project Leader for a Disease-Modifying Osteoarthritis Therapy Project.
Facilitator and Team Member, the Pharmacia Accelerated Discovery / Early Development Initiative
Worked with Discovery project teams on the integration of Marketing, Clinical Research, Safety, and Chemical Scale-up line functions in the project to assure the most rapid progress possible in the identification and advancement of novel potential drugs into clinical trials.
Chemistry Project Leader / Senior Research Advisor, Discovery Medicinal Chemistry, Pharmacia Corp
Chemistry Project Leader in Inflammation/Arthritis Projects.
Chemistry Project Leader, Discovery Medicinal Chemistry, Searle / Monsanto
In collaboration with the Biology Project Leader (together functioning as Project co-leaders), maintained responsibility for the progress of the inducible nitric oxide synthase (iNOS) Inflammation project. Organized and gave scientific guidance to the medicinal chemistry of the project, coordinating activities across the Skokie, IL and Chesterfield, MO chemistry sites. Responsible for the maintenance of excellent communications between chemistry sites and between chemists and biologists. The project succeeded in bringing a compound to clinical trials.
Interim Director, Discovery Medicinal Chemistry, Searle / Monsanto
Upon the resignation of the Director of Medicinal Chemistry, acted as interim Director. Coordinated administrative affairs across the three Medicinal Chemistry sites until selection of the Medicinal Chemistry Director.
Section Head, Department of Chemistry, Searle / Monsanto
Led the chemistry group that developed the enabling synthesis of the antithrombotic Xemilofiban. This synthesis allowed the compound to be made in amounts suitable for clinical evaluation. The same process was then converted to an enantioselective method by Chemical Sciences and used as the manufacturing process until cancellation of the project in Phase III clinical trials.
Section Head, Department of Central Nervous System Diseases Research, Searle / Monsanto
Coordinated medicinal chemical research in the areas of peptide opioid analgesia and prostaglandin antagonist analgesia.
Group Leader II, Department of Central Nervous System Diseases Research, Searle / Monsanto
Led a group working on peptide opioid analgesia and on memory and cognition enhancement via modulation of the NMDA-sensitive glutamate receptor.
Senior Research Scientist / Group Leader II, Dept. of Medicinal Chemistry, G.D. Searle & Co.
Led a group working in the gastrointestinal area on histamine H-2 antagonists, antisecretory antidiarrheals, and therapy for inflammatory bowel disease. Synthesized and obtained a US patent on SC-35803, the active principle of Dipentum brand of olsalazine, which was licensed by Searle to Pharmacia.
Senior Research Investigator, Department of Chemical Research, G.D. Searle & Co
Research Investigator, Department of Chemical Research, G.D. Searle & Co
Co-holder of many patents related to biochemistry and pharmacology, and more.
Numerous publications on topics related to organic biomolecular chemistry, radiopharmaceuticals, nitric oxide, and more.
Numerous presentations on topics related to biochemistry and pharmacology, inflammatory bowel disease, molecular, pharmacological and clinical aspects of nitric oxide, and more.